Risk Management (General)
Cancer Risks: Are We Getting Them Right?
Researching cancer mortality over the past few months has proved to be a bit of an eye-opener, and in three ways: firstly the level of excess mortality seen in a number of cancers, secondly the duration over which an extra risk persists, and thirdly that excess mortality may extend over a considerable period.
Can Big Data Spell the End of Uncertainty?
Big data applications are increasingly shaping our everyday lives, making trends more transparent and patterns more predictable. Like insurance, science, notably medicine, is equally subject to the novel possibilities and demands resulting from big data. Will risks gradually decline as trends and patterns become more predictable in healthcare and for behavior? Are the days of insurance and science as we know them numbered?
Big Data, Big Insight – What Does It Offer to Life Insurers?
In an earlier Risk Insights article, we examined the bold claim for big data that the abundance and speed of information would make knowledge redundant. We concluded that if knowledge is understood as the body of causal explanations for observed statistical correlations, there could indeed be a grain of truth in such a claim, especially in the field of commercial applications.
Insuring HIV - Q&A with Dr. Dan Zimmerman
Recently, RGA’s Dr. Dan Zimmerman spoke to the Association of Home Office Underwriters (AHOU) about the history of HIV/AIDS and insurance, and how risk modeling can reasonably conclude that some individuals with HIV can now be candidates for life insurance coverage. We sat down with Dr. Zimmerman to discuss his presentation and the paradigm shift in the availability of life insurance for people with HIV.
Impaired Risk Review: Crediting Systems
Once upon a time, being a standard risk in the underwriting process was the best you could hope for. It meant that your health was at the top of the group of insured lives being considered and eligible for the best rate, and that you would live all the way out to the prediction of the actuarial life tables. Now, life insurers have created a whole tier of preferred and super preferred pricing that makes a standard issue almost seem like a rated policy.
NT-pro BNP in Risk Assessment of those having Stable Coronary Atherosclerotic Heart Disease (CAD)
N Terminal-pro Brain Natriuretic Peptide (NT-pro BNP) is produced by cardiac muscle cells (myocytes) in response to cardiac wall stress and myocardial ischemia. NT-pro BNP has been shown to predict all-cause mortality in insurance applicants without a history of heart disease, as well as in the general population. It has been found to improve future cardiovascular risk estimation when considered along with classic cardiovascular risk assessors. It has also been identified as an indicator of future mortality risk in those having stable coronary atherosclerotic heart disease (CAD)
Mature Ages and Preferred Underwriting
Preferred underwriting is simply the aggregation of risk into groupings, according to a set of predetermined criteria representing a certain level of risk. Historically, the insurance industry simply classified individuals as either standard or substandard risks.
MIB Mortality Risk Analysis Committee: Diabetes Study (Video)
This video presents findings from a recent study on diabetes conducted by the MIB Mortality Risk Analysis Committee.
The link to the study is here: http://www.mibgroup.com/pdf/2016_06_diabetes_study.pdf
How Biological Age Could Help Insurers Improve Customer Relationships
Ageing is an innate and often emotional process. We generally sense our own ageing in a visceral, illogical way; for example, we could feel rejuvenated by a healthy diet or regular exercise. In fact how we feel could reflect our biological age, which may better indicate our current health status by taking account of improvements and deterioration, than chronological age that increases continually and incrementally.
RGA ReFlections May 2016 Issue
This edition of ReFlections contains an in-depth review of the role of genetics in the rapidly changing diagnostic criteria, risk stratification, and treatment of individuals with chronic lymphocytic leukemia (CLL). RGA also discusses the relatively new but increasingly popular Cancer Reimbursement product and its design, underwriting and claims issues. ReCite, a medical literature review section, has articles of interest to both underwriters and medical directors.